Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Microbot Medical (MBOT) Announces Positive GLP Study Results

by Zacks Equity Research

Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Best Growth Stocks to Buy for January 3rd

by Zacks Equity Research

BROS, DVA and EVBG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 3, 2024.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Ethan Feller headshot

Bull of the Day: DaVita (DVA)

by Ethan Feller

DaVita has a strong long-term stock performance and multiple bullish catalysts

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

Vasundhara Sawalka headshot

5 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like DVA, BECN, CASY, FLR and CWCO that are seeing price strength have a high chance of carrying the momentum forward.

Brookdale (BKD) Concludes Transactions to Extend Debt Repayment

by Zacks Equity Research

Brookdale (BKD) completes two financing transactions to push its debt maturities until September 2025, thereby relieving it from the debt repayment burden for next year and focusing on core operations.

3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio

by Zacks Equity Research

Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.

Three Reasons to Add Ecolab (ECL) Stock to Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) focus on R&D raises optimism about the stock.

The Zacks Analyst Blog Highlights DaVita, GE HealthCare Technologies and Hologic

by Zacks Equity Research

DaVita, GE HealthCare Technologies and Hologic are part of the Zacks top Analyst Blog.

DVA vs. CHE: Which Stock Is the Better Value Option?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Debanjana Dey headshot

3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2024

by Debanjana Dey

Here are some dirt-cheap MedTech value stocks - DVA, GEHC, HOLX - which are expected to provide long-term gains.

McKesson (MCK) Announces Availability of PNH's FDA-Approved Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Should Value Investors Buy DaVita (DVA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Nalak Das headshot

5 S&P 500 Winners of 2023 That Are Must Buys for 2024

by Nalak Das

We have narrowed our search to five S&P 500 stocks. These are: RCL, LYV, AIZ, DVA, AMZN.

Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Best Growth Stocks to Buy for December 22nd

by Zacks Equity Research

DVA, LZ and MPTI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 22, 2023.